SILBER ALLAN C 13D and 13G filings for POINT Biopharma Global Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2023-12-27 5:02 pm Sale |
2023-12-22 | 13D | POINT Biopharma Global Inc. PNT |
SILBER ALLAN C | 0 0.000% |
-9,316,184 (Position Closed) |
Filing |
| 2023-10-03 2:57 pm Purchase |
2023-10-02 | 13D | POINT Biopharma Global Inc. PNT |
SILBER ALLAN C | 9,316,184 8.800% |
84,816 (+0.92%) |
Filing |
| 2022-11-22 4:21 pm Purchase |
2022-11-17 | 13D | POINT Biopharma Global Inc. PNT |
SILBER ALLAN C | 9,231,368 8.740% |
365,580 (+4.12%) |
Filing |
| 2021-07-12 4:37 pm Purchase |
2021-06-30 | 13D | POINT Biopharma Global Inc. PNT |
SILBER ALLAN C | 8,865,788 9.800% |
8,865,788 (New Position) |
Filing |